Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney Disease

• Published in: Journal of the American College of Cardiology 2010-09, Vol.56 (12), p.956-965
• Main Authors: Jardine, Meg J., MBBS, PhD, Ninomiya, Toshiharu, MD, PhD, Perkovic, Vlado, MBBS, PhD, Cass, Alan, MBBS, PhD, Turnbull, Fiona, MBBS, PhD, Gallagher, Martin P., MBBS, MPH, Zoungas, Sophia, MBBS, PhD, Lambers Heerspink, Hiddo J., PharmD, PhD, Chalmers, John, MD, PhD, Zanchetti, Alberto, MD
• Format: Article
• Language: English
• Subjects: aspirin; bleeding; Cardiovascular; cardiovascular risk; chronic kidney disease; Internal Medicine; mortality; primary prevention; risk-benefit analysis
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2010.02.068

Objectives The purpose of this study was to determine the benefit and risk associated with antiplatelet therapy in the chronic kidney disease (CKD) population. Background Cardiovascular and possibly bleeding risks are elevated in patients with CKD. The balance of benefit and harm associated with antiplatelet therapy remains uncertain. Methods The HOT (Hypertension Optimal Treatment) study randomly assigned participants with diastolic hypertension to aspirin (75 mg) or placebo. Study treatment effects were calculated using univariate proportional hazards regression models stratified by baseline estimated glomerular filtration rate (eGFR) with trends tested by adding interaction terms. End points included major cardiovascular events, total mortality, and major bleeding. Results The study included 18,597 participants treated for 3.8 years. Baseline eGFR was